Top

American Journal of Clinical Dermatology

Published in:

01-10-2004 | Adis Spotlight

Spotlight on Adapalene in Acne Vulgaris

Authors: John Waugh, Stuart Noble, Lesley J. Scott

Published in: American Journal of Clinical Dermatology | Issue 5/2004

Abstract

Adapalene (Differin®) is a retinoid agent indicated for the topical treatment of acne vulgaris. In clinical trials, 0.1% adapalene gel has proved to be effective in this indication and was as effective as 0.025% tretinoin gel, 0.1% tretinoin microsphere gel, 0.05% tretinoin cream and 0.1% tazarotene gel once every two days; however, the drug was less effective than once-daily 0.1% tazarotene gel. It can be used alone in mild acne or in combination with antimicrobials in inflammatory acne and has proved efficacious as maintenance treatment. Adapalene has a rapid onset of action and a particularly favorable tolerability profile compared with other retinoids. These attributes can potentially promote patient compliance, an important factor in treatment success. Adapalene is, therefore, assured of a role in the first-line treatment of acne vulgaris.

The use of trade names is for product identification purposes only and does not imply endorsement.

Shroot B. Pharmacodynamics and pharmacokinetics of topical adapalene. J Am Acad Dermatol 1998 Aug; 39 (2 Pt 3): S17–24CrossRef

Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol 1997; 36 (6 Suppl.): S96–103CrossRef

Galderma Laboratories. Differin (adapalene) gel, 0.1%. Product insert information, United States [online]. Available from URL: http://www.differin.com/about/insertadapalenegel.shtml [Accessed 2004 May 4]

Galderma Laboratories. Differin® (adapalene) cream 0.1% product insert information, United States [online]. Available from URL: http://www.differin.com/about/insertadapalene cream.shtml [Accessed 2004 May 4]

Caron D, Clucas A, Dunsire JP, et al. Radiolabelled adapalene is poorly absorbed after topical application of adapalene 0.1% gel. J Eur Acad Dermatol Venerol 1998 Sep; 11 Suppl. 2: 275–6

Medsafe. Information for Health Professionals: data sheet. Differen™ adapalene 0.1% [online]. Available from URL: http://www.medsafe.govt.nz/Profs/Datasheet/d/Differingel.htm [Accessed 2004 May 28]

Cunliffe WJ, Caputo R, Dreno B, et al. Efficacy and safety comparison of adapalene (CD271) gel and tretinoin gel in the topical treatment of acne vulgaris: a European multicentre trial. J Dermatol Treat 1997; 8 (3): 173–8CrossRef

Alirezai M, Meynadier J, Jablonska S, et al. Efficacy and safety comparison study of 0.1% and 0.03% adapalene gels and tretinoin gel in the topical treatment of acne [in French]. Ann Dermatol Venereol 1996; 123 (3): 165–70PubMed

Shalita A, Weiss J, Chalker D, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol 1996 Mar; 34 (3): 482–5PubMedCrossRef

10.

Tu P, Li GQ, Zhu XJ, et al. A comparison of adapalene gel 0.1% vs. tretinoin gel 0.025% in the treatment of acne vulgaris in China. J Eur Acad Dermatol Venereol 2001; 15 Suppl. 3: 31–6PubMedCrossRef

11.

Ellis CN, Millikan LE, Smith EB, et al. Comparison of adapalene 0.1% solution and tretinoin 0.025% gel in the topical treatment of acne vulgaris. Br J Dermatol 1998 Oct; 139 Suppl. 52: 41–7PubMedCrossRef

12.

Grosshans E, Marks R, Mascaro JM, et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol 1998 Oct; 139 Suppl. 52: 26–33PubMedCrossRef

13.

Verschoore M, Langner A, Wolska H, et al. Efficacy and safety of CD 271 alcoholic gels in the topical treatment of acne vulgaris. Br J Dermatol 1991 Apr; 124: 368–71PubMedCrossRef

14.

Cunliffe WJ, Poncet M, Loesche C, et al. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol 1998 Oct; 139 Suppl. 52: 48–56PubMedCrossRef

15.

Cunliffe WJ, Caputo R, Dreno B, et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials. J Am Acad Dermatol 1997 Jun; 36 (6 Pt 2): S126–34CrossRef

16.

Ioannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial. Br J Dermatol 2002 Sep; 147 (3): 523–7PubMedCrossRef

17.

Cunliffe WJ, Orfanos C, Caputo R, et al. Comparison of clinical safety and efficacy of adapalene gel and tretinoin gel in the treatment of acne vulgaris [abstract no. P139]. J Eur Acad Dermatol Venereol 1995 Oct; 5 Suppl. 1: S152CrossRef

18.

Nyirady J, Grossman RM, Nighland M, et al. A comparative trial of two retinoids commonly used in the treatment of acne vulgaris. J Dermatolog Treat 2001 Sep; 12 (3): 149–57PubMedCrossRef

19.

Thiboutot D, Gold MH, Jarratt MT, et al. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis 2001 Oct; 68 (4 Suppl.): 10–9PubMed

20.

Cunliffe WJ, Gollnick H. Currents concepts in the treatment of acne vulgaris [abstract]. European Academy of Dermatology and Venereology Annual Meeting; 2000 Oct 11–15; Geneva

21.

Webster G, Guenther L, Poulin YP, et al. A multicenter, double-blind, randomized comparison of the efficacy and tolerability of treating facial acne vulgaris once daily with tazarotene 0.1% gel or adapalne 0.1% gel. Cutis 2002; 69: 4–11PubMed

22.

Leyden J, Lowe N, Kakita L, et al. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial. Cutis 2001 Jun; 67 (6 Suppl.): 10–6PubMed

23.

Wolf Jr JE, Kaplan D, Kraus SJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol 2003 Sep; 49 (3 Suppl.): S211–7CrossRef

24.

Zhang J, Feng LL, Teng TY, et al. The maintenance effect of a treatment with adapalene gel 0.1% in patients with acne vulgaris previously treated with clindamycin topical solution, 1% alone or in combination with adapalene gel, 0.1% [poster]. The American Academy Of Dermatology 62nd Annual Meeting; 2004 Feb 6–11; Washington, DC

25.

Fang L, Fu W, Gu J, et al. Efficacy and safety of benzoyl peroxide gel, 5% combined with adapalene gel, 0.1% in Chinese patients with acne vulgaris [abstract no. P0020]. Ann Dermatol Venereol 2002 Jul; 129 Suppl.: 374

26.

Cunliffe WJ, Meynadier J, Alirezai M, et al. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. J Am Acad Dermatol 2003 Sep; 49 (3 Suppl.): S218–26CrossRef

27.

Campo MH, Zuluaga A, Escobar P, et al. Efficacy and safety comparison of lymecycline associated with adapalene and minocycline associated with adapalene in the treatment of acne vulgaris [poster]. 20th World Congress of Dermatology; 2002 Jul 1–5; Paris

28.

Cunliffe WJ, Danby FW, Dunlap F, et al. Randomised, controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris. Eur J Dermatol 2002; 12 (4): 350–4PubMed

29.

Dunlap FE, Mills OH, Tuley MR, et al. Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference. Br J Dermatol 1998 Oct; 139 Suppl. 52: 17–22PubMedCrossRef

30.

Savin R, Berger R. A split-face study to compare the safety and efficacy of Avita™ (tretinoin cream) cream 0.025% and Differin™ (adapalene gel) gel 0.1% in subjects with grade II or III acne vulgaris [abstract no. 065]. American Academy of Dermatology 57th Annual Meeting; 1999 Mar 19–24; New Orleans, 65

31.

Dosik JS, Arsonnaud S. Determination of the cumulative irritation potential of adapalene cream and gel 0.1% compared to tretinoin micro, 0.04% amd micro 0.1% after repeated applications to the skin of healthy subjects [poster]. American Academy of Dermatology 62nd Annual Meeting; 2004 Feb 6–11; Washington, DC

32.

Caron D, Sorba V, Clucas A, et al. Skin tolerance of adapalene 0.1% gel in combination with other topical antiacne treatments. J Am Acad Dermatol 1997 Jun; 36 (6 Pt 2): S113–5CrossRef

33.

Galvin SA, Gilbert R, Baker M, et al. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol 1998 Oct; 139 Suppl. 52: 34–40PubMedCrossRef

34.

Queille-Roussel C, Poncet M, Mesaros S, et al. Comparison of the cumulative irritation potential of adapalene gel and cream with that of erythromycin/tretinoin solution and gel and erythromycin/isotretinoin gel. Clin Ther 2001 Feb; 23 (2): 205–12PubMedCrossRef

35.

Toole JWP, Lockhart L, Potrebka J, et al. Comparative irritancy study among retinoid creams and gels. J Cutan Med Surg 1999 Oct; 3 (6): 298–301PubMed

36.

Verschoore M, Poncet M, Czernielewski J, et al. Adapalene 0.1% gel has low skin-irritation potential. J Am Acad Dermatol 1997 Jun; 36 (6 Pt 2): S104–9CrossRef

37.

Brand B, Gilbert R, Baker MD, et al. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol 2003 Sep; 49 (3 Suppl.): S227–32CrossRef

38.

Greenspan A, Loesche C, Vendetti N, et al. Cumulative irritation comparison of adapalene gel and solution with 2 tazarotene gels and 3 tretinoin formulations. Cutis 2003 Jul; 72 (1): 76–81PubMed

Title: Spotlight on Adapalene in Acne Vulgaris
Authors: John Waugh
Stuart Noble
Lesley J. Scott
Publication date: 01-10-2004
Publisher: Springer International Publishing
Published in: American Journal of Clinical Dermatology / Issue 5/2004
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.2165/00128071-200405050-00014

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Spotlight on Adapalene in Acne Vulgaris

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2004

The Potential Role of Allergen-Specific Sublingual Immunotherapy in Atopic Dermatitis

Folliculitis

Management of Cutaneous Warts

Management of Bullous Pemphigoid

Pimozide in Dermatologic Practice

Poly-L-Lactic Acid